Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Research & Development (2016 - 2025)

Historic Research & Development for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to $267.0 million.

  • Teva Pharmaceutical Industries' Research & Development rose 809.72% to $267.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.0 billion, marking a year-over-year increase of 160.32%. This contributed to the annual value of $1.0 billion for FY2025, which is 150.3% up from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Research & Development stood at $267.0 million for Q4 2025, which was up 809.72% from $256.0 million recorded in Q3 2025.
  • Teva Pharmaceutical Industries' Research & Development's 5-year high stood at $269.0 million during Q2 2024, with a 5-year trough of $175.0 million in Q3 2022.
  • Moreover, its 5-year median value for Research & Development was $243.0 million (2021), whereas its average is $238.6 million.
  • Its Research & Development has fluctuated over the past 5 years, first plummeted by 2117.12% in 2022, then skyrocketed by 4457.14% in 2023.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Research & Development stood at $244.0 million in 2021, then fell by 13.93% to $210.0 million in 2022, then increased by 8.1% to $227.0 million in 2023, then rose by 8.81% to $247.0 million in 2024, then rose by 8.1% to $267.0 million in 2025.
  • Its last three reported values are $267.0 million in Q4 2025, $256.0 million for Q3 2025, and $244.0 million during Q2 2025.